The Effectiveness of Telerehabilitation in Liver Transplant Patients

January 9, 2026 updated by: Alper AYAS, Istanbul University - Cerrahpasa

Investigation of the Effectiveness of the Telerehabilitation Program in Patients With Liver Transplantation

Liver transplantation is defined as a surgical procedure in which a liver with tissue damage and inability to perform its functions is replaced, in whole or in part, with a healthy liver obtained from a living or deceased donor. Post-transplantation treatment includes medical treatment, physiotherapy, and rehabilitation. Physiotherapy and rehabilitation, an important component of liver transplantation management, consists of three phases: preoperative, early postoperative, and late postoperative. Telerehabilitation is currently defined as the control or monitoring of rehabilitation remotely using telecommunication-related technologies. Studies on telerehabilitation in liver transplant patients are insufficient in the literature. The aim of this study is to investigate the effect of a telerehabilitation-based exercise program applied to liver transplant patients on exercise capacity, respiratory muscle strength, peripheral muscle strength, fatigue level and quality of life.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Participants will be randomly divided into two groups: a telerehabilitation group and home exercise program group. Both groups will be evaluated before and after treatment (week 8). The telerehabilitation group will receive videoconference-based telerehabilitation three days a week for eight weeks. All exercises will be performed under the supervision of a physiotherapist. Each telerehabilitation session will last approximately 30-45 minutes. The exercises will be performed in the following order: breathing exercises, strengthening exercises, balance exercises, and walking exercises. The home exercise program group will receive an exercise brochure after the initial evaluation. Both groups will continue with their standard medical treatments, and a second evaluation will be conducted at the end of eight weeks. Participants' exercise capacity will be assessed using the "6-Minute Walk Test," fatigue level using "The Fatigue Severity Scale", respiratory muscle strength by measuring "Maximal inspiratory pressure (MIP)" and "Maximal expiratory pressure (MEP)", muscle strength using a digital dynamometer, balance using the "Timed Up and Go Test," and quality of life using the "The Liver Disease Symptom Index 2.0"

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
58

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Turkey (Türkiye)
    • Istanbul
      • Büyükçekmece, Istanbul, Turkey (Türkiye), 34500
        • Istanbul University-Cerrahpasa, Faculty of Health Sciences, Physiotherapy and Rehabilitation Laboratory
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Being between 18-65 years of age and having undergone a liver transplant
  • Having had a liver transplant operation at least 6 months prior
  • Spontaneous breathing
  • Hemodynamic stability
  • Reading and writing skills
  • Ability to mobilize independently, ability to follow verbal and visual instructions

Exclusion Criteria:

  • Presence of unstable cardiovascular disease
  • Presence of primary lung disease requiring regular bronchodilator treatment
  • Presence of neuromuscular disease or neurological complications
  • Musculoskeletal limitation/use of assistive devices
  • Being a multiple organ transplant recipient
  • Presence of orthopedic disability and functional capacity limitation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Home exercise program group
Home exercise program group will initially be given instructions on the exercises and asked to perform them three days a week for eight weeks. They will be contacted by phone once a week to inquire whether they are doing the exercises.
Other: Home exercise
Patients will be given brochures on breathing, strengthening, balance and walking exercises and asked to perform them without a physiotherapist.
Experimental: Telerehabilitation group
The telerehabilitation group will receive videoconference-based telerehabilitation three days a week for eight weeks. All exercises will be performed under the supervision of a physiotherapist.
Other: Telerehabilitation
The telerehabilitation program will include breathing, strengthening, balance, and walking exercises, with increasing intensity week by week, and stretching exercises targeting major muscles will be given during the cool-down period.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
6-Minute Walk Test
Time Frame: eight weeks
Exercise capacity will be assessed using the Six-Minute Walk Test, which plays an important role in evaluating pre- and post-operative exercise performance in liver transplant patients. The test will be conducted in a 30 m long, enclosed, straight corridor under the supervision of a physiotherapist, in accordance with the criteria set by the American Thoracic Society. The patients' heart rate and peripheral capillary oxygen saturation values will be recorded before, during, and after the test using a portable pulse oximeter. Dyspnea and perceived fatigue levels will be assessed using the Modified Borg Scale (MBS) during the test. The total walking distance completed in six minutes will be recorded in meters as the individual's six-minute walk distance
eight weeks
Timed Up and Go Test
Time Frame: eight weeks
Used to evaluate the balance performance of individuals during movement. The person sits in a chair of standard height (46 cm), a distance of 3 meters is measured from the chair and a cone is placed at the end of this distance to indicate it. After receiving the command "walk as fast as you can and sit back down in the chair," the person gets up, walks down the corridor for meters, turns around, walks back to the chair and sits down. The time from the moment of getting up from the chair until the person turns around and sits back down in the chair is measured with a stopwatch and recorded in seconds.
eight weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
The Liver Disease Symptom Index 2.0
Time Frame: eight weeks
The Chronic Liver Disease Quality of Life Scale 2.0 will be used as a disease-specific measurement tool. It is a scale developed to objectively evaluate the clinical and psychological consequences on physical and daily living activities in chronic liver disease and to determine the severity of the disease. The Chronic Liver Disease Quality of Life Scale 2.0 , which has been applied in different stages of chronic liver diseases and psychometrically tested, evaluates the effects of symptoms on daily life as well as symptom severity. It is a useful and practical scale in clinical use, whose validity and reliability have been established in the Turkish population
eight weeks
The Fatigue Severity Scale
Time Frame: eight weeks
The Fatigue Severity Scale (FSS) is a nine-item self-administered scale. The scale correlates moderately well with the Visual Analog Scale (VAS) and is therefore a good tool for assessing the severity of fatigue. Patients are asked to choose a number from 1 to 7 indicating how much they agree or disagree with the statement. "1 point" indicates strong disagreement, "7 points" indicates strong agreement. A score of 4 and above generally indicates severe fatigue.
eight weeks
Respiratory Muscle Strength Measurement
Time Frame: eight weeks
Respiratory muscle strength will be assessed by measuring the maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP), which are intraoral pressure measurements. The measurement will be performed using a portable intraoral pressure gauge with the maximal breathing method while the airway is closed with a valve.
eight weeks
Muscle Strength Measurement
Time Frame: eight weeks
This is a method used to measure muscle strength in patients. A La Fayette handheld digital dynamometer will be used during the test. To obtain isometric contraction during the test, the person performing the measurement is asked to hold the dynamometer steady while the person being tested applies maximum contraction against the device. The patient will be asked to hold the maximal isometric contraction for 5 seconds, followed by a 30-second rest interval and the same procedure will be repeated 3 times on the dominant side and the average of the measurement values will be recorded.
eight weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Istanbul University - Cerrahpasa

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 30, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 30, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 24, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 24, 2025

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 8, 2026

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 9, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IUC-FTR-AA-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings